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Abstract Graves’ disease, an autoimmune disease with
heterogeneous symptoms including Graves’ orbitopathy,
has a combined genetic/environmental background, where
variations within CD28/CTLA-4/ICOS genes are considered
as disease markers.
Association of CD28c.17+3T>C(rs3116496), CTLA-4g.
319C>T(rs5742909), CTLA-4c.49A>G(rs231775), CTLA-
4g.*642AT(8_33), CT60(rs3087243), Jo31(rs11571302),
ICOSc.1554+4GT(8_15) polymorphisms with susceptibility
to Graves’ disease and clinical outcome was investigated.
The study group comprised of 561 Polish Caucasians,
including 172 unrelated Graves’ disease patients. CTLA-
4c.49A>G, CTLA-4g.319C>T, and CT60 were genotyped
by PCR–RFLP; Jo31 and CD28c.17+3C>T by minise-
quencing; CTLA-4g.*642AT(8_33) and ICOSc.1554+




1554+4GT(8_15)(m) and TCA(AT<16)GT(m) haplotypes
increased risk of Graves’ disease, especially in males, as
well as overall Graves’ orbitopathy development with
severe outcome. TCG(AT16–21)GG(l) haplotype increased
risk of Graves’ disease and reduced the chance of successful
medical treatment. Although this haplotype was mainly
observed in patients without signs of Graves’ orbitopathy, if
Graves’ orbitopathy developed it favored a Graves’ orbi-
topathy outcome. Haplotype TCA(AT>21)GT(m) increased
Graves’ disease risk in women and, in all patients, was
linked to Graves’ disease without Graves’ orbitopathy. TCG
(AT<16)GG(m) haplotype was predominantly observed in
patients without Graves’ orbitopathy, whereas TCA
(AT16–21)GG(m) was absent in those patients. TCA
(AT16–21)GG(m) occurred in patients with a mild Graves’
orbitopathy outcome. The marker CTLA-4g.*642AT(8_33)
was the only independent Graves’ disease risk factor,
whereas CT60 was an independent factor for disease pro-
gression. Sporadic Graves’ disease was related to presence
of CTLA-4c.49A>G[A] and the rare CTLA-4g.319C>T[T]
allele variant. Familial background of the disease was
exclusively associated with CTLA-4g.*642AT(8_33)
[AT>21]/[AT>21] genotype. CD28/CTLA-4/ICOS loci may
confer inherited susceptibility to Graves’ disease or may be
involved in susceptibility to Graves’ disease and play a
pathogenetic role.
Keywords CD28/CTLA-4/ICOS ● Graves’ disease ● Graves’
orbitopathy ● Gene polymorphism ● Haplotype
* Edyta Pawlak-Adamska
epawlak@iitd.pan.wroc.pl
1 Department of Experimental Therapy, Hirszfeld Institute of
Immunology and Experimental Therapy, Polish Academy of
Sciences, R. Weigl 12, Wroclaw 53-114, Poland
2 Department of Endocrinology, Diabetes and Isotope Therapy,
Wroclaw Medical University, L. Pasteur 4, Wroclaw 50-367,
Poland
3 Department of Forensic Medicine, Wroclaw Medical University,
M. Curie-Sklodowska 52, Wroclaw 50-369, Poland
4 Department of Human Evolutionary Biology, Institute of
Anthropology, Adam Mickiewicz University, Umultowska 89,
Poznan 61-614, Poland
5 Department of Ophthalmology, Wroclaw Medical University,
Borowska 213, Wroclaw 50-556, Poland
Electronic supplementary material The online version of this article
(doi:10.1007/s12020-016-1096-1) contains supplementary material,
which is available to authorized users.
Introduction
The pathogenesis of Graves’ disease (GD) requires a spe-
ciﬁc sequence of events, involving both genetic factors and
the ensuing environmental factors, for the ﬁnal clinical
phenotype to manifest [1–3]. The orbital inﬂammatory
process in Graves’ orbitopathy (GO) is believed to be dri-
ven by T cells in response to thyroid–orbit shared antigens
accessing and inﬁltrating the orbital space [4]. As T cells
play a key role in the pathogenesis of GO, and CD28/CTLA-
4/ICOS co-stimulatory molecules are critical in T-cell acti-
vation, they may be considered to be candidate risk factors.
Disruption to the precise balance of expression of co-
stimulatory and inhibitory molecules is known to play a role
in the pathogenesis of autoimmune diseases [5]. This is
supported by studies demonstrating that adolescents and
children newly diagnosed with GD had an abnormal
percentage of lymphocytes expressing co-stimulatory
molecules [6, 7]. Similarly, differences in the expression
pattern of CD28 in T cells of the thyroid gland and per-
ipheral blood T lymphocytes was observed [6]. Differential
regulation of these molecules could easily affect T-cell
function and hence the regulation of the immune response.
Abnormal expression and/or dysfunction of these molecules
may be caused by polymorphisms in the corresponding
gene [8–26]. In previous work, we linked the presence of
guanine (G) in CT60 and Jo31 single-nucleotide poly-
morphism (SNPs), located within the 3′UTR of CTLA-4,
with an elevated level of the soluble CTLA-4 isoform in
GD, especially in cases of severe outcome [26]. Competi-
tive binding of sCTLA-4 with CTLA-4 common ligands
inhibited T-cell proliferation via increased activation of
CD28 [27]. The prevalence of sCTLA-4-bearing genetics
in GD may indicate abnormal expression of CTLA-4 on
T-regulatory cells (Treg). In turn, this may affect the precise
balance of suppressive and effector activity of Treg,
which is strongly linked to pathogenesis of autoimmune
diseases [27].
A previously published, candidate gene strategy indi-
cated and validated several immune-related and thyroid-
speciﬁc susceptibility genes for GD. In regard to immune-
related genes, comprehensive ﬁne mapping of the CD28/
CTLA-4/ICOS region showed an association signal within a
6.1-Kb 3′ region of CTLA-4 [18]. To date, most research
has focused on univariate association studies of single
polymorphisms—especially the highly polymorphic CTLA-
4 [8, 9, 16, 18, 21, 25, 28, 29, 30, 31, 32, 33, 34, 35, 36],
with several functional polymorphisms having been
observed within this gene [8–26]. Similar ﬁndings
concerning GO and CTLA-4 polymorphisms have been
reported [37]. In the case of the co-stimulatory receptors
CD28 and ICOS, deﬁnitive determination of their role in
GD and GO pathogenesis is still impossible due to the
paucity of research published to date. In our opinion,
treating the 2q33 chromosomal region where CD28, CTLA-
4, and ICOS are located as a locus is more appropriate and
takes into account the possible effects of interactions
between polymorphisms located within those genes on their
function and/or expression and, consequently, on the
pathogenesis and clinical outcome of GD. Such a relation-
ship was previously observed between genetic variants in
ICOSIVS1+173T/C and CTLA-4 mRNA expression levels
[38].
Based on the concept that the associations of GD and GO
with this region may represent the effects of any of these
three genes alone, or in combination, due to linkage




1302)/ICOSc.1554+4GT(8_15) gene polymorphisms and
susceptibility to GD, as well as the severity and activity of





One hundred and seventy-two unrelated Polish Caucasian
GD patients consecutively admitted to the tertiary care
academic medical center were enrolled into the study. The
initial diagnosis of GD was conﬁrmed by routine clinical
and laboratory tests. Detailed patient characteristics are
presented in Table 1. Ninety-six patients responded to ﬁrst-
line medical treatment and required no further therapy for
relapse within next 18 months.
Assessment of ocular changes
Ophthalmological examination was performed at the time of
blood collection. The severity and activity of orbitopathy
was assessed using criteria proposed by Bartalena [39]
(detailed in Table 1).
Control group
The control group consisted of 389 apparently healthy
volunteers from the same geographical area (225 (57.8 %)
females and 164 (42.2 %) males).
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Ethical approvals
The local ethics committee approved the study protocol.
Genotyping of polymorphisms
The CTLA-4g.319C>T (rs5742909), CTLA-4c.49A>G
(rs231775), CT60 (CTLA-4g.*6230G>A, rs3087243), and
Jo31 (CTLA-4g.*10223G>T, rs11571302) polymorphisms
were examined as described by Daroszewski et al. [26].
The CD28c.17+3T>C SNP (rs3116496, IVS3+17C/T),
CTLA-4g.*642AT(8_33) and ICOSc.1554+4GT(8_15)
short tandem repeat polymorphisms were genotyped
according to Suwalska et al. [40].
Statistical analyses
The Hardy–Weinberg equilibrium (HWE) was tested for the
studied group. Categorical data between GD patients and
controls, and within the GD group according to clinical
outcome, were compared using the χ2 test with appropriate
correction. In case of multiple comparisons, Bonferroni
multiple adjustments were employed. Haplotype analysis
and LD coefﬁcients were estimated using the SHEsis soft-
ware (http://202.120.7.14/analysis/myAnalysis.php).
The combined effects of polymorphic markers and
environmental factors (gender and smoking habits) on the
development of GD and GD outcome were analyzed by
unconditional multivariate logistic regression analysis with
a logit regression model using a quasi-Newton estimation
method (software EPIINFO Ver. 7.1.1.14).
Differences were considered statistically signiﬁcant if the
p-value< 0.05.
Results
Genotype frequencies in both groups were in HWE
(Table 2).
For CTLA-4g.*642AT(8_33) polymorphism, 20 alleles
and 90 genotypes were identiﬁed (data not shown). Alleles
were grouped into three groups for further analysis: [AT<16]
with less than 16, [AT16–21] with 16–21, and [AT>21] with
more than 21 AT repeats.
Table 1 GD patients (n= 172) clinical characteristics
Parameter n (%)
Without GO (n= 28) CAS + orbitopathy index 0 28 (16.28)








Orbitopathy index Non-severe (n= 64) Mild 29 (16.86)
Moderate 35 (20.35)
Severe 80 (46.50)
Gender Female/male 134 (77.90)/38 (22.10)
Familial autoimmune thyroid history Yes/no 138 (80.23)/34 (19.77)
Smoking status Non-smokers (n= 65) Never 65 (37.79)




Response to anti-thyroid treatment Yes 96 (55.82)
No (n= 76) Thyroidectomy 16 (9.30)
131I therapy 60 (34.88)
Age Mean± SD 49± 12.73
Median 48
Range 23–82
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Table 2 CTLA-4g.*642AT(8_32), CT60 (rs3087243, CTLA-4g.*6230G>A), and ICOSc.1554+4GT(8_15) genotype and allele frequencies in GD











[AT<16]/[AT<16] 31 (18.0) 99 (25.4) 0.08^ Referent
[AT<16]/[AT16–21] 52 (30.2) 104 (26.7) 3.10 0.08 1.60 0.95–2.69
[AT<16]/[AT>21] 22 (12.8) 64 (16.5) 0.08 0.77 1.10 0.58–2.06
[AT16–21]/[AT16–21] 35 (20.3) 50 (12.9) 7.26 0.007 2.24 1.24–4.04
[AT16–21]/[AT>21] 30 (17.4) 54 (13.9) 3.53 0.06 1.77 0.97–3.24
[AT>21]/[AT>21] 2 (1.2) 18 (4.6) 1.21* 0.27* 0.35 0.08–1.62
Alleleb
[AT<16] 136 (39.5) 366 (47.0) 0.006^ Referent
[AT16–21] 152 (44.2) 258 (33.2) 10.41 0.001 1.59 1.20–2.10
[AT>21] 56 (16.3) 154 (19.8) 0.01 1.00 0.98 0.68–1.41
Dominant model
[AT<16]/[AT16–21] + [AT16–21]/[AT16–21] + [AT16–21]/[AT>21] vs. others 117 (68.0) 208 (53.5) 10.36 0.001 1.85 1.27–2.70
55 (32.0) 181 (46.5) 0.54 0.37–0.79
CT60 (CTLA-4g.*6230G>A, rs3087243)
Genotypec
[GG] 74 (43.0) 133 (34.3) 0.08^ Referent
[GA] 80 (46.5) 187 (48.2) 1.78 0.18 0.77 0.52–1.13
[AA] 18 (10.5) 68 (17.5) 6.19 0.01 0.48 0.26–0.86
Allele
[G] 228 (66.3) 453 (58.4) 6.09 0.01 1.41 1.08–1.84
[A] 116 (33.7) 323 (41.6) 0.72 0.55–0.93
Dominant model
[GG] + [GA] vs. [AA] 154 (89.7) 320 (82.5) 4.57 0.03 1.82 1.05–3.16
18 (10.3) 68 (17.5) 0.55 0.32–0.96
Recessive model
[AA] + [GA] vs. [GG] 98 (57.0) 255 (65.7) 3.91 0.05 0.69 0.48–1.00
74 (43.0) 134 (34.4) 1.45 1.00–2.09
ICOSc.1554+4GT(8_15)
Genotyped
(s)/(s) 1 (0.6) 4 (1.0) ns^ 0.00* 1.00* 0.58 0.06–5.29
(s)/(m) 5 (2.9) 35 (9.0) 4.46* 0.03* 0.33 0.13–0.88
(s)/(l) 7 (4.1) 17 (4.4) 0.009 1.00 0.96 0.38–2.41
(m)/(m) 71 (41.3) 166 (42.9) Referent
(m)/(l) 77 (44.8) 137 (35.4) 1.77 0.18 1.31 0.88–1.94
(l)/(l) 11 (6.4) 28 (7.2) 0.06 0.81 1.10 0.52–2.32
Allelee
(s) 14 (4.1) 60 (7.8) ns^ 4.58 0.03 0.52 0.29–0.96
(m) 224 (65.1) 504 (65.1) Referent
(l) 106 (30.8) 210 (27.1) 0.74 0.39 0.88 0.67–1.17
Dominant model
(m)/(m) + (m)/(l) vs. others 153 (89.0) 338 (87.3) 0.29 0.59 0.86 0.49–1.50
19 (11.0) 49 (12.7) 1.17 0.67–2.05
Bold indicates statistical signiﬁcant association
ICOSc.1554+4GT(8_15): (s)-short alleles with 8 and 9 repeats of GT pair; (m)-medium alleles with 10 and 11 repeats of GT pair; (l)-long alleles
with 12 or more repeats of GT pair
OR odds ratio, 95 % CI 95 % conﬁdence intervals, HWE Hardy–Weinberg equilibrium
^-p-value after Bonferroni correction; *-p-value after Yate’s correction
a χ2= 13.85, df= 5, p˝= 0.02, nGDpatients= 172, ncontrols= 389
b χ2= 12.51, df= 3, p˝= 0.002
c χ2= 6.40, df= 2, p˝= 0.04, nGDpatients= 172, HWEGDpatients: χ
2= 0.28, p= 0.60, ncontrols= 388, HWEcontrols: χ
2= 0.03, p= 0.87
d χ2= 9.46, df= 5, p˝= 0.09, nGDpatients= 172, ncontrols= 387
e χ2= 6.02, df= 3, p˝= 0.05
Endocrine (2017) 55:186–199 189
For ICOSc.1554+4GT(8_15) polymorphism, 8 alleles
and 19 genotypes were observed (data not shown); alleles
were grouped into three cohorts: short alleles (s) with 8–9,
medium (m) with 10–11, and long alleles (l) with 12 or
more GT repeats.
Smokers were statistically more prone to severe eye
symptoms (p= 0.04), and patients with non-severe GO
were the best responders to anti-thyroid treatment (p=
0.001) (Supplementary Table 1).
CD28/CTLA-4/ICOS gene polymorphisms and GD risk
In univariate analysis a signiﬁcant association with GD was
observed only with two of the studied polymorphisms:
g.*642AT(8_33) and CT60 (rs3087243) (Table 2).
The CTLA-4g.*642AT(8_33)[AT16–21] variant increased
the risk of disease 2.24-fold (p= 0.007, 95 % CI:
1.24–4.04), and the carriers of this allele variant were 1.85
times more prone to GD (p= 0.001, 95 % CI: 1.27–2.70).
CT60 (rs3087243) [AA] homozygosity signiﬁcantly
protected against GD (p= 0.01, OR = 0.48, 95 % CI:
0.26–0.86). Weaker association was seen for overall pre-
sence of this allele (p= 0.03, OR = 0.69, 95 % CI:
0.48–1.00) (Table 2).
Other studied polymorphisms were not associated with
GD risk (Supplementary Table 2).
In the controls robust LD was observed between the pair
of CTLA-4 polymorphisms, and weaker association was
seen between CTLA-4 polymorphisms and CD28c.17
+3T>C (rs3116496), while in patients such relations were
observed only between CTLA-4 gene polymorphisms
(Supplementary Table 3).
Signiﬁcantly different haplotype distribution among GD
patients and controls was observed (χ2= 25.028397,
pcorrected = 0.00069). Haplotypes TCA[AT<16]AT(l), TCG
[AT>21]GG(m) [in order: CD28c.17+3T>C/g.319C>
T/c.49A>G/g.*642AT(8_33)/CT60/Jo31/ICOSc.1554+4GT
(8_15)] decreased the risk of GD (p= 0.029116,
OR = 0.499, 95 % CI: 0.265–0.941; p= 0.000456,
OR = 0.195, 95 % CI: 0.071–0.535), whereas TCG
[AT16–21]GG(l) and TTA[AT>21]GG(m) ampliﬁed such risk
(p= 0.053837, OR = 1.455, 95 % CI: 0.993–2.133;
p= 0.050925, OR = 2.030, 95 % CI: 0.985–4.185)
(Supplementary Table 4).
CD28/CTLA-4/ICOS gene polymorphisms and gender
The CTLA-4g.*642AT(8_33)[AT16–21]/[AT16–21] genotype
increased risk of disease in women (p= 0.01, OR = 2.48),
whereas [AT16–21] allele increased the risk of disease in
both gender (p= 0.007; p= 0.05) (Supplementary Table 5).
Moreover, women possessing the CT60 (rs3087243)
[AA] genotype have lower risk of developing GD (p= 0.02,
OR = 0.43, 95 % CI: 0.22–0.86), similarly was for the allele
and dominant model (p= 0.02; p= 0.02) (Supplementary
Table 5).
There also the ICOSc.1554+4GT(8_15)(l) allele
increased risk of GD in women (p= 0.003, OR= 1.72, 95%
CI: 1.21–2.46) (Supplementary Table 5).
TCG[AT>21]GG(m) haplotype protected against disease
after stratiﬁcation according to gender (p= 0.007, p=
0.008). Moreover, TCA[AT<16]GT(m) and CTA[AT16–21]
GG(l) haplotypes were observed only in male patients, and
TCA[AT<16]AG(m) and TCG[AT16–21]GG(m) haplotypes
increased disease risk in male (p= 0.03, OR= 5.93, 95 %
CI: 0.94–37.51; p= 0.05, OR= 1.93, 95 % CI: 1.00–3.74).
Contrary, haplotypes TCA[AT<16]AT(l), TCG[AT>21]GG
(m), and CTA[AT>21]GG(m) were absent in male patients
(Supplementary Table 6).
Additionally, stratiﬁcation by gender showed differed
frequency of TCA[AT<16]AG(m) and CTA[AT16–21]GG(l)
within GD (p= 0.04, p= 0.001), whereas within controls
this was observed for CTA[AT>21]GG(m) haplotype (p=
0.02) (Supplementary Table 6).
GD risk factors—multivariate associations
The unconditional stepwise multivariate logistic regression
analysis of all studied polymorphisms, including three
prone genetic parameters: presence of T allele at CTLA-
4g.319C>T (rs5742909) (genotype TT and CT), presence
of CTLA-4g.*642AT(8_33)[AT16–21] allele, presence of G
allele at CT60 (rs3087243) [genotype (GG) and (GA)], and
environmental factor—female gender, showed that only the
CTLA-4g.*642AT(8_33) was an independent GD risk fac-
tor (χ2= 33.3, p= 0.0008). In detail, presence of CTLA-4g.
*642AT(8_33)[AT16–21] allele 1.94-fold increased risk for
GD (p= 0.00081, 95 % CI: 1.32–2.86).
CD28/CTLA-4/ICOS gene polymorphisms and clinical
data in GD
Familial autoimmune thyroid history
The CTLA-4g.319C>T (rs5742909) genotype and allele
were differentially distributed (p= 0.0002; p= 4.07 × 10−5),
and lack of the rare [T] allele increased GD in patients with
familial autoimmune thyroid incidence by 4.85-fold (p=
0.00005, 95 % CI: 2.18–10.76). CTLA-4g.*642AT(8_33)
[AT>21]/[AT>21] genotype was also present only in patients
with familial autoimmune thyroid background (pcorrected=
0.04), whereas presence of the CTLA-4c.49A>G (rs231775)
[A] allele variant was signiﬁcantly associated with sporadic
GD (pcorrected = 0.05) (Table 3 and Supplementary Table 7).
A signiﬁcant difference in haplotype frequency in GD
patients with respect to familial thyroid autoimmune history
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Table 3 CTLA-4g.319C>T, CTLA-4c.49A>G, CTLA-4g.*642AT(8_32), ICOSc.1554+4GT(8_15) genotype and allele frequencies in GD patients
according to occurrence of familial autoimmune thyroid history in ﬁrst-line relatives
Familial autoimmune thyroid history χ2 p-value Odds ratio 95 % conﬁdence
interval
Without
(n= 34) n (%)
With
(n= 138) n (%)
CTLA-4 g.319C>T (rs5742909)
Genotypea
[CC] 16 (47.1) 112 (81.2) Referent
[CT] 16 (47.1) 24 (17.4) 14.95 0.0001 0.21 0.09–0.49
[TT] 2 (5.9) 2 (1.4) 2.00* 0.16* 0.14 0.02–1.09
Allele
[C] 48 (70.6) 248 (89.9) 16.87 4.07 × 10−5 3.69 1.92–7.08
[T] 20 (29.4) 28 (10.1) 0.27 0.14–0.52
Dominant model
[CC] + [CT] vs. [TT] 32 (94.1) 136 (98.6) 0.81* 0.37* 4.25 0.58–31.32
2 (5.9) 2 (1.4) 0.24 0.03–1.73
Recessive model
[TT] + [CT] vs. [CC] 18 (52.9) 26 (18.8) 16.66 4.5 × 10−5 0.21 0.09–0.46
16 (47.1) 112 (81.2) 4.85 2.18–10.76
CTLA-4c.49A>G (rs231775)
Genotypeb
[AA] 12 (35.3) 39 (28.3) Referent
[AG] 19 (55.9) 70 (50.7) 0.09 0.76 0.88 0.39–2.01
[GG] 3 (8.8) 29 (21.0) 1.79* 0.18* 2.97 0.77–11.51
Allele
[A] 43 (63.2) 148 (53.6) 2.04 0.15 0.67 0.39–1.16
[G] 25 (36.8) 128 (46.4) 1.49 0.86–2.57
Dominant model
[AA] + [AG] vs. [GG] 31 (91.2) 109 (79.0) 3.85* 0.05* 0.27 0.08–0.94
3 (8.8) 29 (21.0) 3.70 1.07–12.78
Recessive model
[GG] + [AG] vs. [AA] 22 (64.7) 99 (71.7) 0.65 0.42 1.38 0.63–3.07
12 (35.3) 39 (28.3) 0.72 0.33–1.60
CTLA-4 g.*642AT(8_33)
Genotypec
[AT<16]/[AT<16] 6 (17.6) 25 (18.1) Referent
[AT<16]/[AT16–21] 10 (29.4) 42 (30.4) 0.00 1.00 1.01 0.33–3.11
[AT<16]/[AT>21] 6 (17.6) 16 (11.6) 0.46 0.50 0.64 0.18–2.33
[AT16–21]/[AT16–21] 6 (17.6) 29 (21.0) 0.05 0.82 1.16 0.33–4.06
[AT16–21]/[AT>21] 6 (17.6) 24 (17.4) 0.004 1.00 0.96 0.27–3.39
[AT>21]/[AT>21] 0 (0.0) 2 (1.4) 4.27* 0.04* – –
Alleled
[AT<16] 28 (41.2) 108 (39.1) Referent
[AT16–21] 28 (41.2) 124 (44.9) 0.22 0.64 1.15 0.64–2.06
[AT>21] 12 (17.6) 44 (15.9) 0.02 1.00 0.95 0.44–2.04
Dominant model
[AT<16]/[AT16–21] + [AT16–21]/[AT16–21] +
[AT<16]/[AT>21] vs. others
34 (100.0) 136 (98.6) 0.04* 0.85* – –
0 (0.0) 2 (1.4) – –
ICOS c.1554_4GT(8_15)
Genotypee
(s)/(s) 0 (0.0) 1 (0.7) 0.39* 0.53* – –
(s)/(m) 0 (0.0) 5 (3.6) 0.47* 0.49* – –
(s)/(l) 3 (8.8) 4 (2.9) 0.41* 0.52* 0.42 0.09–2.07
(m)/(m) 17 (50.0) 54 (39.1) Referent
(m)/(l) 10 (29.4) 67 (48.6) 2.97 0.08 2.11 0.89–4.98
(l)/(l) 4 (11.8) 7 (5.1) 0.26* 0.61* 0.55 0.14–2.11
Allelef
(s) 3 (4.4) 11 (4.0) 0.03* 0.85* 0.90 0.24–3.35
(m) 44 (647.) 180 (65.2) Referent
(l) 21 (30.9) 85 (30.8) 0.001 1.00 0.99 0.55–1.77
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was observed (χ2Global= 18.40, pcorrected= 0.03). In particular,
haplotypes CCA[AT<16]AT(m) and TTA[AT>21]GG(m)
were signiﬁcantly associated with sporadic GD
(p= 0.055078; p= 0.003176), whereas TCG[AT16–21]GG
(m) was over-represented in patients with familial thyroid
autoimmune history (p= 0.025898) (Supplementary
Table 8).
Response to medical treatment
Univariate analysis revealed signiﬁcant associations of two
CTLA-4 3′UTR SNPs: CT60 (rs3087243) and Jo31
(rs11571302)-genotypes at both polymorphic sites were
differentially distributed with regard to sustained response
to medical treatment (p= 0.007; p= 0.03). Both, the CT60
(rs3087243) [AA] and Jo31 (rs11571302) [TT] homo-
zygosity signiﬁcantly increased the response rate (pcorrected
= 0.007, OR = 0.16, 95 % CI: 0.04–0.60; pcorrected= 0.01,
OR = 0.30, 95 % CI: 0.12–0.79). This was also conﬁrmed at
the allele level (p= 0.002; p= 0.008), and lack of those
alleles statistically signiﬁcantly reduces the success of
medical treatment (p= 0.01, OR = 2.24, 95 % CI:
1.21–4.15; p= 0.02, OR = 2.02, 95 % CI: 1.10–3.89)
(Table 4 and Supplementary Table 9).
Haplotype TTA[AT16–21]GT(l) signiﬁcantly reduced,
whereas TCA[AT<16]AT(m) increased the success of
anti-thyroid treatment (p= 0.008184, OR = 9.048, 95 %
CI: 1.287–63.593; p= 0.007347, OR = 0.438, 95 %
CI: 0.238–0.806, Supplementary Table 10).
Response to medical treatment—multivariate associations
Finally, unconditional stepwise multivariate logistic
regression analysis of all studied polymorphisms, including
three prone genetic parameters: presence of G allele at
CT60 (rs3087243) (genotype [GG] and [GA]), Jo31
(rs11571302) [GG] genotype, and presence of CTLA-4g.
*642AT(8_33)[AT16–21] allele, indicated only the CT60
(rs3087243) marker as an independent disease relapse factor
(χ2= 114.6, p= 0.009). CT60 (rs3087243) [G] allele 4.51-
fold decreased success of anti-thyroid treatment (p= 0.02,
95 % CI: 1.24–16.3).
CD28/CTLA-4/ICOS gene polymorphisms and GO
The course of GO—univariate associations
The CTLA-4g.*642AT(8_33)[AT16–21] homozygosity
increased the risk of GO 2.42-fold (p= 0.004, 95 %
CI: 1.31–4.46). Moreover, the same genotype was asso-
ciated with GO severity (p= 0.0001, OR= 4.55, 95 %
CI: 2.01–10.31; p= 0.01, OR= 3.91, 95 % CI: 1.33–11.49),
but favored the inactive outcome (p= 0.004, OR = 3.37,
95 % CI: 1.44–7.89). The same observation was true for
allele (Table 5, Supplementary Tables 11 and 12).
Concerning CT60 (rs3087243), the [AA] genotype sig-
niﬁcantly reduced the risk of GO and heavy GO outcome:
severe eye symptoms as well as active GO course (p= 0.02,
OR = 0.48, 95 % CI: 0.26–0.90; p= 0.01, OR= 0.35, 95 %
CI: 0.15–0.83; p= 0.02, OR= 0.35, 95 % CI: 0.14–0.86),
which was also true for presence of [A] allele (p= 0.02, OR
= 0.64, 95 % CI: 0.43–0.94; p= 0.02, OR = 0.55, 95 % CI:
0.34–0.90; p= 0.05, OR = 0.60, 95 % CI: 0.36–1.00)
(Table 5, Supplementary Tables 11 and 12).
Although the association of CTLA-4g.319C>T
(rs5742909) with GO development was observed only at the
allele level (p= 0.04) (Table 5), this SNP was associated
with GO outcome (Supplementary Table 11). The rare [T]
Table 3 continued
Familial autoimmune thyroid history χ2 p-value Odds ratio 95 % conﬁdence
interval
Without
(n= 34) n (%)
With
(n= 138) n (%)
Dominant model
(s)/(m) + (m)/(m) + (m)/(l) vs. others 27 (79.4) 126 (91.3) 3.92 0.05 2.72 0.98–7.55
7 (20.6) 12 (8.7) 0.37 0.13–1.02
CTLA-4g.319C>T (rs5742909) Whole genotype a χ2= 16.89, df= 2, p= 0.0002
CTLA-4c.49A>G (rs231775) Whole genotype b χ2= 2.78, df= 2, p= 0.25
CTLA-4g.*642AT(8_33) Whole genotype c χ2= 1.44, df= 5, p= 0.92
Whole allele d χ2= 0.33, df= 2, p= 0.85
ICOSc.1554+4GT(8_15) Whole genotype e χ2= 8.75, df= 5, p= 0.12
Whole allele f χ2= 0.026678, df= 2, p= 0.986749
Bold indicates statistical signiﬁcant association
ICOSc.1554+4GT(8_15): (s)-short alleles with 8 and 9 repeats of GT pair; (m)-medium alleles with 10 and 11 repeats of GT pair; (l)-long alleles
with 12 or more repeats of GT pair
^-p-value after Bonferroni correction; *p-value after Yate’s correction; ˝-global p-value for genotype
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Table 4 CTLA-4g.*642AT(8_32), CT60 (rs3087243, CTLA-4g.*6230G>A), Jo31 (CTLA-4g.*10223G>T) genotype and allele frequencies in GD
patients with respect to response to anti-thyroid treatment








[AT<16]/[AT<16] 22 (22.9) 9 (11.8) Referent
[AT<16]/[AT16–21] 28 (29.2) 24 (31.6) 2.38 0.12 2.10 0.81–5.41
[AT<16]/[AT>21] 13 (13.5) 9 (11.8) 0.81 0.37 1.69 0.54–5.35
[AT16–21]/[AT16–21] 20 (20.8) 15 (19.7) 1.36 0.24 1.83 0.66–5.11
[AT16–21]/[AT>21] 13 (13.5) 17 (22.4) 4.76 0.03 3.20 1.11–9.22
[AT>21]/[AT>21] 0 (0.0) 2 (2.6) 1.66* 0.20* – –
Alleled
[AT<16] 85 (44.3) 51 (33.6) Referent
[AT16–21] 81 (42.2) 71 (46.7) 2.49 0.11 1.46 0.91–2.34
[AT>21] 26 (13.5) 30 (19.7) 4.20 0.04 1.92 1.03–3.61
Dominant model
[AT<16]/[AT16–21] + [AT16–21]/[AT16–21] +
[AT<16]/[AT>21] vs. others
61 (63.5) 56 (73.7) 2.01 0.16 1.61 0.83–3.10
35 (36.5) 20 (26.3) 0.62 0.32–1.20
CT60(CTLA-4)(g.*6230G>A, rs3087243)
Genotypee
[GG] 33 (34.4) 41 (53.9) Referent
[GA] 48 (50.0) 32 (42.1) 3.66 0.06 0.54 0.28–1.02
[AA] 15 (15.6) 3 (3.9) 7.22* 0.007* 0.16 0.04–0.60
Allele
[G] 114 (59.4) 114 (75.0) 9.27 0.002 2.05 1.29–3.27
[A] 78 (40.6) 38 (25.0) 0.49 0.31–0.78
Dominant model
[GG] + [GA] vs. [AA] 81 (84.4) 73 (96.1) 4.99* 0.03* 4.51 1.25–16.20
15 (15.6) 3 (3.9) 0.22 0.06–0.80
Recessive model
[AA] + [GA] vs. [GG] 63 (63.6) 35 (46.1) 6.63 0.01 0.45 0.24–0.83
33 (34.4) 41 (53.9) 2.24 1.21–4.15
Jo31 (CTLA-4)(g.*10223G>T, rs11571302)
Genotypef
[GG] 28 (29.2) 35 (46.1) Referent
[GT] 47 (49.0) 33 (43.4) 2.89 0.09 0.56 0.29–1.10
[TT] 21 (21.9) 8 (10.5) 6.24 0.01 0.30 0.12–0.79
Allele
[G] 103 (53.6) 103 (67.8) 7.04 0.008 1.82 1.17–2.83
[T] 89 (46.4) 49 (32.2) 0.55 0.35–0.86
Dominant model
[GG] + [GT] vs. [TT] 75 (78.1) 68 (89.5) 3.90 0.05 2.38 0.99–3.73
21 (21.9) 8 (10.5) 0.42 0.17–1.01
Recessive model
[TT] + [GT] vs. [GG] 68 (70.8) 41 (53.9) 5.21 0.02 0.48 0.26–0.91
28 (29.2) 35 (46.1) 2.07 1.10–3.89
CTLA-4g.*642AT(8_33) Whole genotype c χ2= 7.52, df= 5, p= 0.19
Whole allele d χ2= 4.86, df= 2, p= 0.09
CT60 (CTLA-4g.*6230G>A, rs3087243) Whole genotype e χ2= 9.87, df= 2, p= 0.007
Jo31 (CTLA-4g.*10223G>T, rs11571302) Whole genotype f χ2= 6.82, df= 2, p= 0.03
Bold indicates statistical signiﬁcant association
^-p-value after Bonferroni correction; *-p-value after Yate’s correction; ˝-global p-value for genotype
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Table 5 CTLA-4g.319C>T (rs5742909), CTLA-4g.*642AT(8_32), CT60 (rs3087243, CTLA-4g.*6230G>A) genotype and allele frequencies in
GD patients stratiﬁed by occurrence of GO and in control group
Control














[CC] 309 (80.3) 23 (82.1) 105 (72.9) Referent
[CT] 74 (19.2) 4 (14.3) 36 (25.0) I:II 0.89 0.35 0.65 0.26–1.60
I:III 2.40 0.12 1.43 0.91–2.23
II:III 0.91* 0.34* 1.97 0.64–6.09
[TT] 2 (0.5) 1 (3.6) 3 (2.1) I:II 0.60* 0.44 8.13 0.71–93.74
I:III 1.55* 0.21* 4.41 0.73–26.78
II:III 0.09* 0.76* 0.66 0.07–6.61
Allele
[C] 692 (89.9) 50 (89.3) 246 (85.4) I:II 2.28 0.13 0.56 0.27–1.20
I:III 4.13 0.04 0.66 0.44–0.99
II:III 0.58 0.44 0.70 0.28–1.74
[T] 78 (10.1) 6 (10.7) 42 (14.6) I:II 2.28 0.13 1.77 0.84–3.77
I:III 4.13 0.04 1.51 1.01–2.27
II:III 0.58 0.44 1.42 0.57–3.53
Dominant model
[CC] + [CT] vs. [TT] 383 (99.5) 27 (96.4) 141 (97.9) I:II 0.47* 0.49* 0.14 0.01–1.61
I:III 1.32* 0.25* 0.25 0.04–1.48
II:III 0.04* 0.84* 1.74 0.17–17.37
2 (0.5) 1 (3.6) 3 (2.1) I:II 0.47* 0.49* 7.09 0.62–80.72
I:III 1.32* 0.25* 4.07 0.67–24.64
II:III 0.04* 0.84* 0.57 0.06–5.73
Recessive model
[TT] + [CT] vs. [CC] 76 (19.7) 5 (17.9) 39 (24.8) I:II 0.00* 1.00* 0.88 0.33–2.40
I:III 3.32* 0.07* 0.66 0.42–1.03
II:III 0.62* 0.43* 1.71 0.61–4.81
309 (80.3) 23 (82.1) 105 (72.9) I:II 0.00* 1.00* 1.13 0.42–3.07
I:III 3.32* 0.07* 1.51 0.97–2.36
II:III 0.62* 0.43* 0.59 0.21–1.65
CTLA-4g.*642AT(8_33)
Genotypec
[AT<16]/[AT<16] 99 (25.4) 4 (14.3) 27 (18.8) Referent
[AT<16]/[AT16–21] 104 (26.7) 12 (42.9) 40 (27.8) I:II 2.48* 0.12* 2.86 0.89–9.15
I:III 1.45 0.23 1.41 0.81–2.47
II:III 0.72* 0.40* 0.49 0.14–1.69
[AT<16]/[AT>21] 64 (16.5) 2 (7.1) 20 (13.9) I:II 0.02* 1.00* 0.77 0.14–4.35
I:III 0.16 0.69 1.15 0.59–2.21
II:III 0.00* 1.00* 1.48 0.25–8.90
[AT16–21]/[AT16–21] 50 (12.9) 2 (7.1) 33 (22.9) I:II 0.19* 0.67* 0.99 0.18–5.59
I:III 8.22 0.004 2.42 1.31–4.46
II:III 0.34* 0.56* 2.44 0.42–14.38
[AT16–21]/[AT>21] 54 (13.9) 6 (21.4) 24 (16.7) I:II 1.52* 0.22* 2.75 0.74–10.17
I:III 2.24 0.13 1.63 0.86–3.10
II:III 0.16* 0.69* 0.59 0.15–2.35
[AT>21]/[AT>21] 18 (4.6) 2 (7.1) 0 (0.0) I:II 0.35* 0.55* 2.75 0.47–16.15
I:III 3.45* 0.06* – –
II:III 4.62* 0.03* – –
Alleled
[AT<16] 366 (47.0) 22 (39.3) 114 (39.6) ns Referent
[AT16–21] 258 (33.2) 22 (39.3) 130 (45.1) I:II 1.26 0.26 1.42 0.77–2.62
I:III 10.10 0.001 1.62 1.20–2.18
II:III 0.16 0.69 1.14 0.60–2.17
[AT>21] 154 (19.8) 12 (21.4) 44 (15.3) I:II 0.49 0.48 1.30 0.63–2.69
I:III 0.18 0.67 0.92 0.62–1.36
II:III 0.75 0.39 0.71 0.32–1.55
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allele was associated with active GO (p= 0.002, OR = 2.08,
95 % CI: 1.29–3.37; p= 0.04, OR = 2.05, 95 %
CI: 1.04–4.40). A more evident association was observed
when the presence of this allele was considered (p= 0.002,
OR = 2.35, 95 % CI: 1.36–4.05; p= 0.01, OR= 2.67, 95 %
CI: 1.24–5.76) (Supplementary Table 12).
Table 5 continued
Control
















203 (53.6) 20 (71.4) 97 (67.4) I:II 3.36 0.07 2.17 0.93–5.04
I:III 8.12 0.004 1.79 1.20–2.68
II:III 0.18 0.67 0.83 0.34–2.01
176 (46.4) 8 (28.6) 47 (32.6) I:II 3.36 0.07 0.46 0.20–1.07
I:III 8.12 0.004 0.56 0.37–0.84
II:III 0.18 0.67 1.21 0.50–2.95
CT60 (CTLA-4)(g.*6230G>A, rs3087243)
Genotypee
[GG] 133 (34.3) 9 (32.1) 65 (45.1) Referent
[GA] 187 (48.2) 17 (60.7) 63 (43.8) I:II 0.48 0.49 1.34 0.58–3.11
I:III 2.79 0.09 0.69 0.46–1.04
II:III 2.23 0.13 0.51 0.21–1.24
[AA] 68 (17.5) 2 (7.1) 16 (11.1) I:II 0.56* 0.46* 0.43 0.09–2.07
I:III 5.47 0.02 0.48 0.26–0.90
II:III 0.08* 0.78* 1.11 0.22–5.64
Allele
[G] 453 (58.4) 35 (62.5) 193 (67.0) I:II 0.37 0.55 1.19 0.68–2.08
I:III 6.57 0.01 1.45 1.09–1.93
II:III 0.43 0.51 1.22 0.67–2.21
[A] 323 (41.6) 21 (37.5) 95 (33.0) I:II 0.37 0.55 0.84 0.48–1.47
I:III 6.57 0.01 0.69 0.52–0.92
II:III 0.43 0.51 0.82 0.45–1.49
Dominant model
[GG] + [GA] vs. [AA] 320 (82.5) 26 (92.9) 128 (88.9) I:II 1.34* 0.25* 2.76 0.64–11.92
I:III 3.25 0.07 1.70 0.95–3.04
II:III 0.08* 0.77* 0.62 0.13–2.84
68 (17.5) 2 (7.1) 16 (11.1) I:II 1.34* 0.25* 0.36 0.08–1.56
I:III 3.25 0.07 0.59 0.33–1.05
II:III 0.08* 0.77* 1.63 0.35–7.50
Recessive model
[AA] + [GA] vs. [GG] 255 (65.7) 19 (67.9) 79 (54.9) I:II 0.06 0.80 1.11 0.49–2.52
I:III 5.14 0.02 0.64 0.43–0.94
II:III 1.62 0.20 0.58 0.24–1.36
134 (34.4) 9 (32.1) 65 (45.1) I:II 0.06 0.80 0.90 0.40–2.05
I:III 5.14 0.02 1.57 1.06–2.31
II:III 1.62 0.20 1.74 0.74–4.10
Bold indicates statistical signiﬁcant association
CTLA-4g.319C>T (rs5742909): GD patients without GO vs. control group: χ2= 3.70, df= 2, p= 0.16; GD patients with GO vs. control group: χ2
= 5.12, df= 2, p= 0.08; GD patients without GO vs. GD patients with GO: χ2= 1.65, df= 2, p= 0.44
CTLA-4g.*642AT(8_32): Genotype: GD patients without GO vs. control group: χ2= 7.25, df= 5, p= 0.20; GD patients with GO vs. control
group: χ2= 16.53, df= 5, p= 0.006; GD patients without GO vs. GD patients with GO: χ2= 16.31, df= 5, p= 0.006
CTLA-4g.*642AT(8_32): Allele: GD patients without GO vs. control group: χ2= 1.33, df= 2, p= 0.51; GD patients with GO vs. control group: χ2
= 13.19, df= 2, p= 0.001; GD patients without GO vs. GD patients with GO: χ2= 1.45, df= 2, p= 0.48
CT60 (CTLA-4g.*6230G>A, rs3087243): GD patients without GO vs. control group: χ2= 2.54, df= 2, p= 0.28; GD patients with GO vs. control
group: χ2= 6.51, df= 2, p= 0.04; GD patients without GO vs. GD patients with GO: χ2= 2.72, df= 2, p= 0.26
OR odds ratio, 95 % CI 95 % conﬁdence intervals
^-p-value after Bonferroni correction; *p-value after Yate’s correction
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Albeit the CTLA-4c.49A>G (rs231775) and Jo31
(rs11571302) SNPs were not related to GO development,
they were associated with the GO outcome (Supplementary
Table 12). The CTLA-4c.49A> [G] allele favored severe
disease outcome (p= 0.04, OR = 1.63, 95 % CI:
1.01–2.61), which was conﬁrmed when the recessive model
([GG] + [AG]vs.[AA]) was adopted (p= 0.03, OR = 1.89,
95 % CI: 1.06–3.36; p= 0.007, OR = 2.70, 95 % CI:
1.30–5.61) (Supplementary Table 12).
When GO is present, carriers of Jo31 (rs11571302) [TT]
genotype were protected against severe eye symptoms
(p= 0.04, OR = 0.37, 95 % CI: 0.14–0.96), which was
conﬁrmed in a dominant model ([GG] + [GT] vs. [TT])
(p= 0.04, OR = 0.61, 95 % CI: 0.38–0.98; p= 0.05, OR =
0.43, 95 % CI: 0.18–1.02) (Supplementary Table 12).
The course of GO—haplotype associations
A statistically signiﬁcant difference in haplotype distribu-
tion between GD patients regarding GO occurrence and
healthy controls was observed (Supplemental Table 13).
When severity and activity status were taken into account,
different global haplotypes distribution was seen in case of
absence of GO symptoms compared to severity and activity
status, but they did not reach statistical signiﬁcance (in both
pcorrected = 0.06) (Supplemental Table 14). Haplotype TCG
[AT16–21]GG(m) favors not only direct GO development,
but also the severe and active GO course (p= 0.015201;
p= 0.015448; p= 0.015266) (Supplementary Tables 13
and 14).
Heavy outcome of GO were also promoted by TCG
[AT16–21]GG(m), TCA[AT<16]GT(m), and TCA[AT>21]AT
(m) haplotypes (Supplemental Table 14), while haplotypes
CCG[AT16–21]GG(m), TCG[AT>21]GG(m), TCG[AT<16]
GG(l), TCA[AT<16]GG(m), TCA[AT<16]GT(l), and
TCA[AT16–21]GG(m) were linked to non-severe mild GO
outcome. TCA[AT<16]AT(l) haplotype protected against an
active course of eye changes (Supplementary Table 14).
In contrast, haplotypes TCA[AT>21]GG(m) and TCG
[AT<16]GG(m) directly favored light GO outcome without
clinical eye symptoms (p= 0.000174; p= 0.015662)
(Supplementary Table 13), which were also conﬁrmed
within GO stratiﬁed according to activity and severity
(p= 0.038863; p= 0.030938; p= 0.012530) (Supplemen-
tary Table 14).
Haplotype TCG[AT>21]GG(m) was statistically sig-
niﬁcantly more frequent in healthy persons (p= 0.003529;
p= 0.029963) (Supplementary Tables 13 and 14).
The course of GO—multivariate associations
The unconditional multivariate logistic regression analysis
of all studied polymorphisms, including four prone genetic
parameters: presence of [G] allele at CTLA-4c.49A>G
(rs231775) (genotype [GG] and [AG]), presence of [G]
allele at CT60 (rs3087243) (genotype [GG] and [GA]),
presence of CTLA-4g.*642AT(8_33)[AT16–21] allele, Jo31
(rs11571302) [GG] genotype and environmental factors:
smoking and male gender, showed that presence of CTLA-
4g.*642AT(8_33)[AT16–21] allele (p= 0.04, OR = 2.10,
95 % CI: 1.03–4.27) and male gender (p= 0.00008,
OR = 4.29, 95 % CI: 2.11–8.72) were independent risk
factors for GO (χ22= 24.1, p= 0.00001).
Discussion
Since a number of studies have established a central role for
T cells in GD [2, 5–7], the region containing genes
encoding the immune regulatory molecules, CTLA-4,
CD28, and ICOS, is good candidate for disease risk factor.
Selected for our study polymorphic sites located within
genes encoded, these co-stimulatory molecules had to have
been reported to be associated with altered immune
response and/or susceptibility to autoimmune disease [9, 13,
18–22, 24–26]. Based on the fact that all three genes are
close to one another within the chromosomal region 2q33,
and that LD was observed between polymorphisms located
within these genes, we postulated that the association
between GD (and/or its clinical phenotype) and this region
might represent the effects of a combination of polymorphic
variations of these three genes. We therefore looked for a
possible association of studied polymorphisms as one sus-
ceptible genetic region deﬁned as a haplotype block with
the GD phenotype.
Our study indicated speciﬁc haplotypes signiﬁcantly
linked with sporadic GD and haplotypes over-represented in
patients with a familial history of thyroid disease. These
results led us to the conclusion that patients with sporadic
incidence and those with a familial background of GD are
characterized by a combination of various markers, and it is
therefore possible that they are genetically different. These
markers may be predictive factors for the development of
GD in families in whom thyroid disease is observed.
Although the 2q33 chromosomal region is linked to GD, the
association between the two was found to be different in
female and male subjects. Our group of patients was too
small for stratiﬁcation by gender at the haplotype level in
the context of GO outcome, therefore the possibility that
differences in our overall population at the univariate level
will also be true in GO subgroups cannot be excluded.
To date, no literature concerning such a relationship has
been published. In terms of predicting the clinical outcome,
two speciﬁc haplotypes are possible: one reducing
(TTA[AT16–21]GT(l)) and another (TCA[AT<16]AT(m))
increasing the successful outcome of anti-thyroid treatment.
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The roles of genetic factors in the GO pathomechanism
are not well characterized. Although a genetic predisposi-
tion to GD has been conﬁrmed, to increase one’s
risk of developing the disease, the signiﬁcance of
genotype–phenotype correlations in GD remains spec-
ulative, and the results of family-based studies are con-
ﬂicting. So far—and only at a univariate level—
polymorphisms located in CTLA-4 have been linked to GO
risk and outcome predictors. Therefore, we tested the
combined impact of the 2q33 region and GO course, and
observed statistically signiﬁcantly different haplotype
associations in GO status. In our search for deeper insight,
speciﬁcally GO course (severity and activity), the differ-
ences were more evident. Particularly, one speciﬁc haplo-
type TCG[AT16–21]GG(m) favored not only the
development of GO but also a severe outcome. The hap-
lotypes TCA[AT>21]GG(m) and TCG[AT<16]GG(m), on
the other hand, were directly linked to GD without any eye
symptoms. As this study is the ﬁrst association analysis
based on the aforementioned concept, our observations
require conﬁrmation by future studies. It must be noted that
we were able to collect a relatively large cohort of patients
with severe eye symptoms and compare them with subjects
with the milder form of GO.
When we used the classical approach—a univariate
association model—the association with GD in our southern
Polish population was seen only in case of two poly-
morphisms located within the CTLA-4 3′UTR region: CT60
(rs3087243) and g.*642AT(8_33). When we looked deeper,
taking ancestral background into account, three CTLA-4
polymorphic variants (g.319C>T (rs5742909) [CC],
c.49A>G (rs231775) [G], g.*642AT(8_33)[AT>21]/
[AT>21]) were associated with the family burden of GD.
This ﬁnding may provide some evidence in support of our
hypothesis; speciﬁcally that the superiority of the associa-
tion deﬁned as one susceptible locus expressed as the
haplotype over the individual polymorphism association. As
compared to other studies, which describe only univariate
analyses [28, 29, 30, 31], our research takes a deeper and
more detailed approach. The most GD-essential genetic
marker in our study, CTLA-4g.*642AT(8_33), was also
relevant in other populations [2, 18, 25]. Importantly, this
marker has functional implications; speciﬁcally the long
AT-repeat allele is associated with reduced control of T-cell
proliferation and thus contributes to the pathogenesis of
GD [25].
Other Polish studies [29, 30, 31] focused mostly on
CTLA-4c.49A>G (rs231775) and revealed a signiﬁcant
association of this marker with disease; however, we did
not. On the other hand, the association of the marker CT60
(rs3087243) observed in our group was not as signiﬁcant as
in another study of Polish patients with GD [29]. Our
observation of a signiﬁcant association of the CT60
(rs3087243) [G] allele aligns with the results of other
reports [9, 18, 28], including a large meta-analysis where
this polymorphic site strongly increased GD risk [28].
Since the goal of anti-thyroid drug therapy (to restore an
euthyroid state) may be achieved in up to 50 % of GD
patients, deﬁning the genetic predictors of remission could
be helpful in clinical practice; therefore, we tested studied
markers to forecast the clinical outcome. At a univariate
level, CT60 (rs3087243) [AA] and Jo31 (rs11571302) [TT]
homozygosity signiﬁcantly increased the success of anti-
thyroid treatment, but multivariate logistic regression ana-
lysis only pointed CT60 (rs3087243) as an independent risk
factor for disease progression.
Previous studies focusing on the CTLA-4c.49A>G
(rs231775) polymorphism [32, 33, 34, 35] showed its
association with a lower chance of remission after dis-
continuation of propylthiouracil treatment [32, 33, 34],
indicating that GD patients with the CTLA-4c.49A>G
(rs231775) [GG] genotype may not be the best candidates
for anti-thyroid drug therapy. Moreover, GD patients with
the [G] allele at this SNP needed to continue anti-thyroid
drug treatment for longer periods to achieve remission,
indicating that this polymorphic variant may be an indicator
of poor prognosis [33, 34]. In contrast, but in line with our
results, Kim et al. [35] did not observe such a relationship
when it came to CTLA-4g.319C>T (rs5742909) and CTLA-
4c.49A>G (rs231775). So far, no research has assessed the
impact of CD28 and ICOS variation on the success of
medical treatment, and only variation within CTLA-4 has
been documented to be a prognostic factor for remission of
disease after treatment. The observed association is prob-
ably due to the functional consequence of studied poly-
morphic markers.
We found an association between CTLA-4 polymorphic
variations and the development and course of GO on a
univariate level. If severity of GO was considered an out-
come, associations were observed in the case of markers for
CTLA-4c.49A>G (rs231775), CTLA-4g.*642AT(8_33),
CT60 (rs3087243), and Jo31 (rs11571302). When looking
for a combined effect (genetics and environment), CTLA-
4g.*642AT(8_33) and male gender were found to be
independent risk factors for GO. CTLA-4c.49A>G
(rs231775) was linked to GO course but not development.
A large meta-analysis [37] of inconsistent results of studies,
focusing on the association between CTLA-4 gene poly-
morphisms and GO, revealed no evidence in support of an
association between this SNP and eye changes.
Moreover, in the one-marker association analysis no
relationship between studied polymorphisms within CD28
and ICOS and GD or the course of the disease was observed
in the overall group association analysis. Our results con-
ﬁrmed previous data showing a lack of association between
these polymorphic sites and GD [9, 27]. The absence of a
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relationship between the CD28c.17+3T>C (rs3116496)
SNP and the disease was evidenced by the lack of impact on
thyroid antibody production [35]; however, stratiﬁcation by
gender showed that females with long alleles at the
ICOSc.1554+4GT(8_15) polymorphic site were more prone
to GD. This is the ﬁrst gender-stratiﬁed analysis; therefore,
corroboration by future studies is necessary.
We, and others, have provided evidence to support the
idea that, in a single gene polymorphic variation, changes
within CTLA-4 may be considered to be GD risk factors and
factors capable of modifying the clinical course of the dis-
ease. We also postulated that because of the location—in
one common chromosomal region—and LD, the analyzed
CD28/CTLA-4/ICOS gene polymorphic variability should
be considered at the haplotype level, rather than by the
single-marker model. Moreover, since GD and GO are
associated with gender and familial autoimmune thyroid
history, these factors should also be taken into account
when a patient’s genetic background is analyzed.
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